MEA Genetic Testing Market - Industry Trends and Forecast to 2029

Description

List of Tables

Middle East and Africa genetic testing market is projected to register a CAGR of 13.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Middle East and Africa Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive And Presymptomatic Testing, Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, Other Diseases) End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, Private Laboratories), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Middle East and Africa genetic testing market are:

Increase in the adoption of next generation sequencing
Technological advancement in genetic testing

Market Players:

The key market players for Middle East and Africa genetic testing market are listed below:

Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Illumina, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Myriad Genetics, Inc.
Abbott
Eurofins Scientific
Biocartis
PacBio
BioReference
Natera, Inc.
Others

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES

4.3 STRATEGIC INITIATIVES:

4.4 CONCLUSION:

4.5 INDUSTRY INSIGHTS
- 4.5.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
- 4.5.2 GENETIC TESTS PRICING
- 4.5.3 KEY INSIGHTS

5 EPIDERMIOLOGY

6 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS
- 7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
- 7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
- 7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER
- 7.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
7.2 RESTRAINTS
- 7.2.1 HIGH COST OF GENETIC TESTING
- 7.2.2 CYBER SECURITY CONCERNS IN GENOMICS
7.3 OPPORTUNITIES
- 7.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
- 7.3.2 TECHNOLOGICAL ADVANCEMENT
- 7.3.3 INCREASING RESEARCH AND DEVELOPMENT
- 7.3.4 RISING DISPOSABLE INCOME
7.4 CHALLENGES
- 7.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
- 7.4.2 STRINGENT REGULATION POLICY

8 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE

8.1 OVERVIEW
8.2 DIAGNOSTIC TESTING
8.3 PRENATAL TESTING
- 8.3.1 NON-INVASIVE SCREENING
  - 8.3.1.1 BY SCREENING METHOD
    - 8.3.1.1.1 WHOLE GENOME SEQUENCING
    - 8.3.1.1.2 COUNTING OF cfDNA FRAGMENTS
    - 8.3.1.1.3 OTHERS
  - 8.3.1.2 BY CONDITION
    - 8.3.1.2.1 TRISOMY 21
    - 8.3.1.2.2 KLINEFELTER SYNDROME
    - 8.3.1.2.3 JACOBS SYNDROME
    - 8.3.1.2.4 CYSTIC FIBROSIS
    - 8.3.1.2.5 TURNER SYNDROME
    - 8.3.1.2.6 TRISOMY 18
    - 8.3.1.2.7 HEMOPHILIA
    - 8.3.1.2.8 TRISOMY 13
    - 8.3.1.2.9 MICRODELETION SYNDROME
    - 8.3.1.2.10 FETAL GENDER
    - 8.3.1.2.11 OTHERS
  - 8.3.1.3 BY SCREENING TYPE
    - 8.3.1.3.1 CARRIER SEQUENCING
    - 8.3.1.3.2 SEQUENTIAL SEQUENCING
- 8.3.2 MATERNAL SERUM QUAD SCREENING
8.4 NEW BORN SCREENING
8.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
8.6 CARRIER TESTING
- 8.6.1 BY TEST TYPE
  - 8.6.1.1 MOLECULAR SCREENING TEST
  - 8.6.1.2 BIOCHEMICAL SCREENING TEST
- 8.6.2 BY TYPE
  - 8.6.2.1 EXPANDED CARRIER SCREENING
    - 8.6.2.1.1 PREDESIGNED PANEL TESTING
    - 8.6.2.1.2 CUSTOM-MADE PANEL TESTING
  - 8.6.2.2 TARGETED DISEASE CARRIER SCREENING
    - 8.6.2.2.1 BY MEDICAL CONDITION
    - 8.6.2.2.2 HEMATOLOGICAL CONDITIONS
    - 8.6.2.2.3 PULMONARY CONDITIONS
    - 8.6.2.2.4 NEUROLOGICAL CONDITIONS
    - 8.6.2.2.5 OTHER CONDITIONS
8.7 OTHER TYPES

9 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY

9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION
- 9.2.1 REAL-TIME PCR (QPCR)
- 9.2.2 DIGITAL PCR (DPCR)
- 9.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
- 9.2.4 HOT-START PCR
- 9.2.5 MULTIPLEX PCR
- 9.2.6 OTHER PCR
9.3 DNA SEQUENCING (NGS-BASED TESTING)
- 9.3.1 NEXT GENERATION SEQUENCING (NGS)
- 9.3.2 SANGER SEQUENCING (SINGLE GENE)
- 9.3.3 OTHER
9.4 WHOLE GENOME SEQUENCING
9.5 MICROARRAYS
- 9.5.1 DNA MICROARRAYS
- 9.5.2 PROTEIN MICROARRAYS
- 9.5.3 OTHER MICROARRAYS
9.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
9.7 OTHERS

10 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY DISEASES

10.1 OVERVIEW
10.2 CANCER
- 10.2.1 BREAST
- 10.2.2 COLON
- 10.2.3 LUNG
- 10.2.4 PROSTATE
- 10.2.5 OTHERS
10.3 SICKLE CELL ANEMIA
10.4 THALASSEMIA
10.5 RARE GENETIC DISORDER
- 10.5.1 TRISOMY 21
- 10.5.2 MONOSOMY X
- 10.5.3 TRISOMY 13
- 10.5.4 MICRODELETION SYNDROME
- 10.5.5 TRISOMY 18
- 10.5.6 OTHERS
10.6 FRAGILE X SYNDROME
10.7 DUCHENNE MUSCULAR DYSTROPHY
10.8 HUNTINGTON'S DISEASE
10.9 CYSTIC FIBROSIS
10.10 OTHERS

11 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY END USER

11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 PRIVATE CLINICS
11.6 LABORATORY SERVICE PROVIDERS
11.7 PRIVATE LABORATORIES

12 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY REGION

12.1 MIDDLE EAST & AFRICA
- 12.1.1 SOUTH AFRICA
- 12.1.2 SAUDI ARABIA
- 12.1.3 U.A.E.
- 12.1.4 ISRAEL
- 12.1.5 EGYPT
- 12.1.6 REST OF MIDDLE EAST AND AFRICA

13 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 ILLUMINA, INC.
- 15.1.1 COMPANY SNAPSHOT
- 15.1.2 COMPANY SHARE ANALYSIS
- 15.1.3 PRODUCT PORTFOLIO
- 15.1.4 RECENT DEVELOPMENT
  - 15.1.4.1 ACQUISITION
  - 15.1.4.2 COLLABORATION
15.2 CEPHEID
- 15.2.1 COMPANY SNAPSHOT
- 15.2.2 REVENUE ANALYSIS
- 15.2.3 COMPANY SHARE ANALYSIS
- 15.2.4 PRODUCT PORTFOLIO
- 15.2.5 RECENT DEVELOPMENT
  - 15.2.5.1 BUSINEES EXPANSION
15.3 FULGENT GENETICS
- 15.3.1 COMPANY SNAPSHOT
- 15.3.2 REVENUE ANALYSIS
- 15.3.3 COMPANY SHARE ANALYSIS
- 15.3.4 PRODUCT PORTFOLIO
- 15.3.5 RECENT DEVELOPMENT
  - 15.3.5.1 ACQUISITION
15.4 PERKINELMER INC.
- 15.4.1 COMPANY SNAPSHOT
- 15.4.2 REVENUE ANALYSIS
- 15.4.3 COMPANY SHARE ANALYSIS
- 15.4.4 PRODUCT PORTFOLIO
- 15.4.5 RECENT DEVELOPMENT
  - 15.4.5.1 PRODUCT LAUNCH
15.5 THERMO FISHER SCIENTIFIC INC.
- 15.5.1 COMPANY SNAPSHOT
- 15.5.2 REVENUE ANALYSIS
- 15.5.3 COMPANY SHARE ANALYSIS
- 15.5.4 PRODUCT PORTFOLIO
- 15.5.5 RECENT DEVELOPMENT
  - 15.5.5.1 COLLABORATION
15.6 ABBOTT
- 15.6.1 COMPANY SNAPSHOT
- 15.6.2 REVENUE ANALYSIS
- 15.6.3 PRODUCT PORTFOLIO
- 15.6.4 RECENT DEVELOPMENT
15.7 BIOCARTIS
- 15.7.1 COMPANY SNAPSHOT
- 15.7.2 REVENUE ANALYSIS
- 15.7.3 PRODUCT PORTFOLIO
- 15.7.4 RECENT DEVELOPMENT
  - 15.7.4.1 PARTNERSHIP
  - 15.7.4.2 AGREEMENT
15.8 BIO-HELIX
- 15.8.1 COMPANY SNAPSHOT
- 15.8.2 PRODUCT PORTFOLIO
- 15.8.3 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
- 15.9.1 COMPANY SNAPSHOT
- 15.9.2 REVENUE ANALYSIS
- 15.9.3 PRODUCT PORTFOLIO
- 15.9.4 RECENT DEVELOPMENTS
  - 15.9.4.1 ACQUISITION
  - 15.9.4.2 PARTNERSHIP
15.10 BIOREFERENCE
- 15.10.1 COMPANY SNAPSHOT
- 15.10.2 REVENUE ANALYSIS
- 15.10.3 PRODUCT PORTFOLIO
- 15.10.4 RECENT DEVELOPMENT
  - 15.10.4.1 ACQUISITION
15.11 ELITECHGROUP
- 15.11.1 COMPANY SNAPSHOT
- 15.11.2 PRODUCT PORTFOLIO
- 15.11.3 RECENT DEVELOPMENTS
  - 15.11.3.1 PRODUCT LAUNCH
  - 15.11.3.2 BUSINESS EXPANSION
15.12 EUROFINS SCIENTIFIC
- 15.12.1 COMPANY SNAPSHOT
- 15.12.2 REVENUE ANALYSIS
- 15.12.3 PRODUCT PORTFOLIO
- 15.12.4 RECENT DEVELOPMENT
  - 15.12.4.1 PRODUCT LAUNCH
15.13 EUGENE LABS
- 15.13.1 COMPANY SNAPSHOT
- 15.13.2 PRODUCT PORTFOLIO
- 15.13.3 RECENT DEVELOPMENT
15.14 F. HOFFMANN-LA ROCHE LTD)
- 15.14.1 COMPANY SNAPSHOT
- 15.14.2 REVENUE ANALYSIS (PARENT COMPANY)
- 15.14.3 PRODUCT PORTFOLIO
- 15.14.4 RECENT DEVELOPMENTS
  - 15.14.4.1 PRODUCT LAUNCH
15.15 GENES2ME
- 15.15.1 COMPANY SNAPSHOT
- 15.15.2 PRODUCT PORTFOLIO
- 15.15.3 RECENT DEVELOPMENT
15.16 INVITAE CORPORATION
- 15.16.1 COMPANY SNAPSHOT
- 15.16.2 REVENUE ANALYSIS
- 15.16.3 PRODUCT PORTFOLIO
- 15.16.4 RECENT DEVELOPMENTS
15.17 MAPMYGENOME
- 15.17.1 COMPANY SNAPSHOT
- 15.17.2 PRODUCT PORTFOLIO
- 15.17.3 RECENT DEVELOPMENT
15.18 MEDGENOME
- 15.18.1 COMPANY SNAPSHOT
- 15.18.2 PRODUCT PORTFOLIO
- 15.18.3 RECENT DEVELOPMENT
15.19 MYRIAD GENETICS
- 15.19.1 COMPANY SNAPSHOT
- 15.19.2 REVENUE ANALYSIS
- 15.19.3 PRODUCT PORTFOLIO
- 15.19.4 RECENT DEVELOPMENT
15.20 NATERA, INC.
- 15.20.1 COMPANY SNAPSHOT
- 15.20.2 PRODUCT PORTFOLIO
- 15.20.3 RECENT DEVELOPMENT
  - 15.20.3.1 PARTNERSHIP
15.21 OTOGENRTICS
- 15.21.1 COMPANY SNAPSHOT
- 15.21.2 PRODUCT PORTFOLIO
- 15.21.3 RECENT DEVELOPMENT
15.22 PACBIO
- 15.22.1 COMPANY SNAPSHOT
- 15.22.2 REVENUE ANALYSIS
- 15.22.3 PRODUCT PORTFOLIO
- 15.22.4 RECENT DEVELOPMENT
15.23 QIAGEN
- 15.23.1 COMPANY SNAPSHOT
- 15.23.2 PRODUCT PORTFOLIO
- 15.23.3 RECENT DEVELOPMENTS
  - 15.23.3.1 PARTNERSHIP
  - 15.23.3.2 PRODUCT LAUNCH
15.24 SEMA4 OPCO, INC.
- 15.24.1 COMPANY SNAPSHOT
- 15.24.2 REVENUE ANALYSIS
- 15.24.3 PRODUCT PORTFOLIO
- 15.24.4 RECENT DEVELOPMENT
15.25 SORENSON GENOMICS
- 15.25.1 COMPANY SNAPSHOT
- 15.25.2 PRODUCT PORTFOLIO
- 15.25.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 70
TABLE 2 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 71
TABLE 3 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 71
TABLE 4 MIDDLE EAST & AFRICA DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 5 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 73
TABLE 6 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 73
TABLE 7 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 73
TABLE 8 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 73
TABLE 9 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 74
TABLE 10 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 74
TABLE 11 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 74
TABLE 12 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 75
TABLE 13 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 77
TABLE 14 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 77
TABLE 15 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 77
TABLE 16 MIDDLE EAST & AFRICA NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 17 MIDDLE EAST & AFRICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 79
TABLE 18 MIDDLE EAST & AFRICA PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 19 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 20 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 81
TABLE 21 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 81
TABLE 22 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 81
TABLE 23 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 82
TABLE 24 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 82
TABLE 25 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 82
TABLE 26 MIDDLE EAST & AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 83
TABLE 27 MIDDLE EAST & AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 83
TABLE 28 MIDDLE EAST & AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 83
TABLE 29 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 84
TABLE 30 MIDDLE EAST & AFRICA OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 85
TABLE 31 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 89
TABLE 32 MIDDLE EAST & AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 90
TABLE 33 MIDDLE EAST & AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 90
TABLE 34 MIDDLE EAST & AFRICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 92
TABLE 35 MIDDLE EAST & AFRICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 92
TABLE 36 MIDDLE EAST & AFRICA WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 93
TABLE 37 MIDDLE EAST & AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 94
TABLE 38 MIDDLE EAST & AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 94
TABLE 39 MIDDLE EAST & AFRICA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 95
TABLE 40 MIDDLE EAST & AFRICA OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 41 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 100
TABLE 42 MIDDLE EAST & AFRICA CANCER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 101
TABLE 43 MIDDLE EAST & AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 101
TABLE 44 MIDDLE EAST & AFRICA SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 103
TABLE 45 MIDDLE EAST & AFRICA THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 103
TABLE 46 MIDDLE EAST & AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 104
TABLE 47 MIDDLE EAST & AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 105
TABLE 48 MIDDLE EAST & AFRICA FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 49 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 107
TABLE 50 MIDDLE EAST & AFRICA HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 108
TABLE 51 MIDDLE EAST & AFRICA CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 109
TABLE 52 MIDDLE EAST & AFRICA OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 109
TABLE 53 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 113
TABLE 54 MIDDLE EAST & AFRICA HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 114
TABLE 55 MIDDLE EAST & AFRICA CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 115
TABLE 56 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 115
TABLE 57 MIDDLE EAST & AFRICA PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 116
TABLE 58 MIDDLE EAST & AFRICA LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 117
TABLE 59 MIDDLE EAST & AFRICA PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION) 117
TABLE 60 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 123
TABLE 61 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 123
TABLE 62 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 123
TABLE 63 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 124
TABLE 64 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 124
TABLE 65 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 124
TABLE 66 MIDDLE EAST & AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 124
TABLE 67 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 125
TABLE 68 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 125
TABLE 69 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 125
TABLE 70 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 126
TABLE 71 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 126
TABLE 72 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 126
TABLE 73 MIDDLE EAST & AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 127
TABLE 74 MIDDLE EAST & AFRICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 127
TABLE 75 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 127
TABLE 76 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 127
TABLE 77 2MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 128
TABLE 78 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
TABLE 79 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 128
TABLE 80 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 128
TABLE 81 MIDDLE EAST & AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
TABLE 82 MIDDLE EAST & AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 129
TABLE 83 MIDDLE EAST & AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 129
TABLE 84 MIDDLE EAST & AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 129
TABLE 85 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 129
TABLE 86 MIDDLE EAST & AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 130
TABLE 87 MIDDLE EAST & AFRICA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 130
TABLE 88 MIDDLE EAST & AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 130
TABLE 89 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 131
TABLE 90 MIDDLE EAST & AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 131
TABLE 91 MIDDLE EAST & AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 132
TABLE 92 MIDDLE EAST & AFRICA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 132
TABLE 93 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 133
TABLE 94 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 133
TABLE 95 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 133
TABLE 96 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
TABLE 97 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 134
TABLE 98 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 134
TABLE 99 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 134
TABLE 100 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 135
TABLE 101 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 135
TABLE 102 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 135
TABLE 103 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 136
TABLE 104 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 136
TABLE 105 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 136
TABLE 106 SOUTH AFRICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 136
TABLE 107 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 137
TABLE 108 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 137
TABLE 109 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 137
TABLE 110 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 137
TABLE 111 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 137
TABLE 112 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 138
TABLE 113 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 138
TABLE 114 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 138
TABLE 115 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 138
TABLE 116 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 138
TABLE 117 SOUTH AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 139
TABLE 118 SOUTH AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 139
TABLE 119 SOUTH AFRICA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 139
TABLE 120 QSOUTH AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 140
TABLE 121 SOUTH AFRICA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 140
TABLE 122 SOUTH AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 140
TABLE 123 SOUTH AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 141
TABLE 124 SOUTH AFRICA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 141
TABLE 125 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
TABLE 126 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 142
TABLE 127 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 142
TABLE 128 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 143
TABLE 129 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 143
TABLE 130 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 143
TABLE 131 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 143
TABLE 132 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 144
TABLE 133 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 144
TABLE 134 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 144
TABLE 135 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 145
TABLE 136 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 145
TABLE 137 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 145
TABLE 138 SAUDI ARABIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
TABLE 139 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 146
TABLE 140 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 146
TABLE 141 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 146
TABLE 142 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
TABLE 143 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 146
TABLE 144 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 147
TABLE 145 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 147
TABLE 146 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 147
TABLE 147 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 147
TABLE 148 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 148
TABLE 149 SAUDI ARABIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 148
TABLE 150 SAUDI ARABIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 148
TABLE 151 SAUDI ARABIA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 149
TABLE 152 SAUDI ARABIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 149
TABLE 153 SAUDI ARABIA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 149
TABLE 154 SAUDI ARABIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 150
TABLE 155 SAUDI ARABIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 150
TABLE 156 SAUDI ARABIA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 150
TABLE 157 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
TABLE 158 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 151
TABLE 159 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 151
TABLE 160 4U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
TABLE 161 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 152
TABLE 162 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 152
TABLE 163 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 152
TABLE 164 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 153
TABLE 165 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 153
TABLE 166 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 153
TABLE 167 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 154
TABLE 168 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 154
TABLE 169 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 154
TABLE 170 U.A.E. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 154
TABLE 171 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 155
TABLE 172 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 155
TABLE 173 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 155
TABLE 174 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
TABLE 175 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 155
TABLE 176 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 156
TABLE 177 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
TABLE 178 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 156
TABLE 179 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 156
TABLE 180 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 157
TABLE 181 U.A.E. GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 157
TABLE 182 U.A.E. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 157
TABLE 183 U.A.E. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 158
TABLE 184 U.A.E. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 158
TABLE 185 U.A.E. GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 158
TABLE 186 U.A.E. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 159
TABLE 187 U.A.E. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 159
TABLE 188 U.A.E. GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 159
TABLE 189 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
TABLE 190 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 160
TABLE 191 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 160
TABLE 192 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
TABLE 193 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 161
TABLE 194 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 161
TABLE 195 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION) 161
TABLE 196 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 162
TABLE 197 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 162
TABLE 198 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 162
TABLE 199 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 163
TABLE 200 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 163
TABLE 201 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 163
TABLE 202 ISRAEL NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 163
TABLE 203 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 164
TABLE 204 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 164
TABLE 205 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 164
TABLE 206 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 164
TABLE 207 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 164
TABLE 208 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 165
TABLE 209 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 165
TABLE 210 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 165
TABLE 211 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 165
TABLE 212 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 166
TABLE 213 ISRAEL GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 166
TABLE 214 ISRAEL POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 166
TABLE 215 ISRAEL DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 167
TABLE 216 ISRAEL MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 167
TABLE 217 ISRAEL GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 167
TABLE 218 ISRAEL RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 168
TABLE 219 ISRAEL CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 168
TABLE 220 ISRAEL GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 168
TABLE 221 EGYPT GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 169
TABLE 222 EGYPT GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 169
TABLE 223 EGYPT GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 169
TABLE 224 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
TABLE 225 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 170
TABLE 226 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 170
TABLE 227 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLIONS) 170
TABLE 228 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS) 171
TABLE 229 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP) 171
TABLE 230 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION) 171
TABLE 231 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION) 172
TABLE 232 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS) 172
TABLE 233 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP) 172
TABLE 234 EGYPT NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 172
TABLE 235 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION) 173
TABLE 236 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS) 173
TABLE 237 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP) 173
TABLE 238 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 173
TABLE 239 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 173
TABLE 240 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 174
TABLE 241 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 174
TABLE 242 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 174
TABLE 243 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 174
TABLE 244 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION) 174
TABLE 245 EGYPT GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 175
TABLE 246 EGYPT POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 175
TABLE 247 EGYPT DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 175
TABLE 248 EGYPT MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION) 176
TABLE 249 EGYPT GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 176
TABLE 250 EGYPT RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 176
TABLE 251 EGYPT CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION) 177
TABLE 252 EGYPT GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION) 177
TABLE 253 REST OF MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION) 178
TABLE 254 REST OF MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS) 178
TABLE 255 REST OF MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP) 178

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: SEGMENTATION 31
FIGURE 2 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: DATA TRIANGULATION 34
FIGURE 3 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: DROC ANALYSIS 35
FIGURE 4 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS 38
FIGURE 7 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: DBMR MARKET POSITION GRID 39
FIGURE 8 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: APPLICATION COVERAGE GRID 40
FIGURE 9 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS 41
FIGURE 10 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: SEGMENTATION 45
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 46
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GENETIC TESTING MARKET IN 2022 & 2029 46
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 47
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA GENETIC TESTING MARKET 57
FIGURE 15 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TYPE, 2021 67
FIGURE 16 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TYPE, 2022-2029 (USD MILLION) 68
FIGURE 17 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TYPE, CAGR (2022-2029) 68
FIGURE 18 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE 69
FIGURE 19 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2021 86
FIGURE 20 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION) 87
FIGURE 21 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2022-2029) 87
FIGURE 22 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE 88
FIGURE 23 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY DISEASES, 2021 97
FIGURE 24 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY DISEASES, 2022-2029 (USD MILLION) 98
FIGURE 25 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY DISEASES, CAGR (2022-2029) 98
FIGURE 26 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE 99
FIGURE 27 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY END USER, 2021 110
FIGURE 28 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY END USER, 2022-2029 (USD MILLION) 111
FIGURE 29 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY END USER, CAGR (2022-2029) 111
FIGURE 30 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE 112
FIGURE 31 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: SNAPSHOT (2021) 119
FIGURE 32 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY COUNTRY (2021) 120
FIGURE 33 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY COUNTRY (2022 & 2029) 120
FIGURE 34 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY COUNTRY (2021 & 2029) 121
FIGURE 35 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: BY TYPE (2022-2029) 121
FIGURE 36 MIDDLE EAST & AFRICA GENETIC TESTING MARKET: COMPANY SHARE 2021 (%) 178